Revilab Anti-A.G.E. dāvanā ar vienreizēju pirkumu virs 350€
Valsts:
Latvia
Valoda:
Latviešu
Valūta:
EUR
LV
€
Mainīt reģionālos iestatījumus
Valsts:
Latvia
Valoda:
Latviešu
Valūta:
EUR
LV
€
Mainīt reģionālos iestatījumus
Angiopathy and retinal degeneration, dry macular degeneration, glaucoma, cataract
Dalīties
Kursa apraksts
for the treatment of angiopathy, glaucoma, cataracts
The isolated peptides prevent the development of retinal degeneration, normalize metabolism and prevent the development of retinal degeneration and optic nerve atrophy.
*In case of wet macular degeneration, edema, hemorrhages in the retina, only Visoluten and Retisil can be used. In retinal sclerosis (fibrosis), the use of retinal peptides is contraindicated.
for the treatment of angiopathy, glaucoma, cataracts
The isolated peptides prevent the development of retinal degeneration, normalize metabolism and prevent the development of retinal degeneration and optic nerve atrophy.
*In case of wet macular degeneration, edema, hemorrhages in the retina, only Visoluten and Retisil can be used. In retinal sclerosis (fibrosis), the use of retinal peptides is contraindicated.
First month
for the treatment of angiopathy, glaucoma, cataracts
for the treatment of angiopathy, glaucoma, cataracts
114.00 €
| Revilab ML 03 | Prevent optic nerve atrophy |
| Pinalex | Prevent retinal degeneration |
Second month
for the treatment of angiopathy, glaucoma, cataracts
for the treatment of angiopathy, glaucoma, cataracts
297.00 €
| Visoluten №60 | Prevent the development of the retinal degeneration |
| Церлутен №60 | Prevent the development of the retinal degeneration |
| Ventfort №60 | Normalizes the condition of the vascular wall |
Third month
for the treatment of angiopathy, glaucoma, cataracts
for the treatment of angiopathy, glaucoma, cataracts
297.00 €
| Visoluten №60 | Prevent the development of the retinal degeneration |
| Церлутен №60 | Prevent the development of the retinal degeneration |
| Ventfort №60 | Normalizes the condition of the vascular wall |
Fourth month
for the treatment of angiopathy, glaucoma, cataracts
for the treatment of angiopathy, glaucoma, cataracts
77.00 €
| Retisil | Promotes a noticeable improvement in blood circulation and metabolism in the retina |
| Revilab SL 02 | It normalizes vascular permeability; reduces the appearance of local inflammatory reaction; stimulates repair processes in diseases and injuries of the retina. |
| Pinalex Tab | Stimulation of regenerative processes in the eye tissues at increased fatigue, diseases accompanied by decreased visual activity |
Whole course
for the treatment of angiopathy, glaucoma, cataracts
for the treatment of angiopathy, glaucoma, cataracts
785.00 €
| Revilab ML 03 | Prevent optic nerve atrophy |
| Pinalex | Prevent retinal degeneration |
| Visoluten №60 | Prevent the development of the retinal degeneration |
| Церлутен №60 | Prevent the development of the retinal degeneration |
| Ventfort №60 | Normalizes the condition of the vascular wall |
| Visoluten №60 | Prevent the development of the retinal degeneration |
| Церлутен №60 | Prevent the development of the retinal degeneration |
| Ventfort №60 | Normalizes the condition of the vascular wall |
| Retisil | Promotes a noticeable improvement in blood circulation and metabolism in the retina |
| Revilab SL 02 | It normalizes vascular permeability; reduces the appearance of local inflammatory reaction; stimulates repair processes in diseases and injuries of the retina. |
| Pinalex Tab | Stimulation of regenerative processes in the eye tissues at increased fatigue, diseases accompanied by decreased visual activity |
| Nosaukums | Daudzums | Lietošanas norādījumi | Darbības mehānisms | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||